Literature DB >> 27044430

Antinuclear antibody testing: discordance between commercial laboratories.

Aryeh M Abeles1, Manuel Gomez-Ramirez2, Micha Abeles3, Shyoko Honiden4.   

Abstract

Antinuclear antibody (ANA) test results frequently affect the course of patients' evaluations, diagnosis, and treatment, but different laboratory centers may yield conflicting results. This study investigated the degree of agreement between laboratory results in a group of subjects who had ANA testing performed at two commercial laboratories. This was a chart review study, in which all ANA tests ordered by the authors from one commercial laboratory over a 4-year period were queried. Corresponding patient charts were reviewed, and if ANA testing had also been performed at the second commercial laboratory, subjects were entered into the study. The primary measurement was agreement between paired ANA results, and we performed sensitivity analysis using varying criteria defining agreement (criteria A to criteria D [strictest to most lenient definition of agreement]). Other data captured included relevant data obtained through the course of evaluation (e.g., presenting complaints, exam findings, other laboratory data) and final diagnoses. Of 101 paired ANA tests, there was 18 % agreement according to the strictest criteria and 42 % according to the most lenient. Of the seven subjects with ANA-associated rheumatic disease, none of the paired tests were in agreement according to criteria A (two agreed according to criteria D). Our findings demonstrate poor agreement between paired ANA tests performed at two commercial laboratories. The low level of agreement may have far-reaching clinical implications. Specifically, this finding calls into question the reliability of ANA testing as it is currently performed and suggests that results may in part depend upon the laboratory center to which patients are referred.

Entities:  

Keywords:  Antinuclear antibodies; Autoantibodies; Connective tissue disease

Mesh:

Substances:

Year:  2016        PMID: 27044430     DOI: 10.1007/s10067-016-3241-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

1.  Prevalence of antinuclear autoantibodies in the serum of normal blood dornors.

Authors:  Solange Assuncion Villagra Fernandez; Alice Zoghbi Coelho Lobo; Zilda Najjar Prado de Oliveira; Ligia Maria Ichimura Fukumori; Alexandre Marques P rigo; Evandro A Rivitti
Journal:  Rev Hosp Clin Fac Med Sao Paulo       Date:  2004-01-28

2.  Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays.

Authors:  W Emlen; L O'Neill
Journal:  Arthritis Rheum       Date:  1997-09

3.  Clinical utility of ANA measured by ELISA compared with ANA measured by immunofluorescence.

Authors:  Gerald A Maguire; Amel Ginawi; Jeffrey Lee; Anita Y N Lim; Graham Wood; Sally Houghton; Dinakantha S Kumararatne; Hill J S Gaston
Journal:  Rheumatology (Oxford)       Date:  2009-06-02       Impact factor: 7.580

4.  Detection and identification of antinuclear antibodies (ANA) in a large community hospital.

Authors:  G Verstegen; M C Duyck; P Meeus; I Ravelingien; K De Vlam
Journal:  Acta Clin Belg       Date:  2009 Jul-Aug       Impact factor: 1.264

5.  Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting.

Authors:  Sonali Narain; Hanno B Richards; Minoru Satoh; Marlene Sarmiento; Richard Davidson; Jonathan Shuster; Eric Sobel; Paulette Hahn; Westley H Reeves
Journal:  Arch Intern Med       Date:  2004 Dec 13-27

6.  Usefulness of antinuclear antibody testing to screen for rheumatic diseases.

Authors:  P N Malleson; M Sailer; M J Mackinnon
Journal:  Arch Dis Child       Date:  1997-10       Impact factor: 3.791

7.  Antinuclear antibody testing. A study of clinical utility.

Authors:  C A Slater; R B Davis; R H Shmerling
Journal:  Arch Intern Med       Date:  1996-07-08

8.  The clinical utility of a positive antinuclear antibody test result.

Authors:  Aryeh M Abeles; Micha Abeles
Journal:  Am J Med       Date:  2013-02-08       Impact factor: 4.965

9.  Screening for antinuclear antibodies by enzyme immunoassay.

Authors:  T D Jaskowski; C Schroder; T B Martins; C L Mouritsen; C M Litwin; H R Hill
Journal:  Am J Clin Pathol       Date:  1996-04       Impact factor: 2.493

Review 10.  Clinical utility of antinuclear antibody tests in children.

Authors:  Julie L McGhee; Lauren M Kickingbird; James N Jarvis
Journal:  BMC Pediatr       Date:  2004-07-09       Impact factor: 2.125

View more
  3 in total

1.  A Multicenter Analysis of Subjectivity of Indirect Immunofluorescence Test in Antinuclear Antibody Screening.

Authors:  Vildan Turan Faraşat; Talat Ecemiş; Yavuz Doğan; Aslı Gamze Şener; Gülfem Terek Ece; Pınar Erbay Dündar; Tamer Şanlidağ
Journal:  Arch Rheumatol       Date:  2019-04-22       Impact factor: 1.472

2.  The SLE-key test serological signature: new insights into the course of lupus.

Authors:  Chaim Putterman; David S Pisetsky; Michelle Petri; Roberto Caricchio; Alan H B Wu; Ignacio Sanz; Jim C Oates; Steve Wallace; Rachel Sorek; Robert Gerwien; Pennina Safer; Keren Jakobi-Brook; Irun R Cohen
Journal:  Rheumatology (Oxford)       Date:  2018-09-01       Impact factor: 7.580

Review 3.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.